Vaccine-induced CD8 T cells are redirected with peptide-MHC class I-IgG antibody fusion proteins to eliminate tumor cells in vivo

References

• Galluzzi L, Martin P. CARs on a highway with roadblocks. Oncoimmunology. 2017;6(12):e1388486. doi:https://doi.org/10.1080/2162402X.2017.1388486.
   PubMed Web of Science ®Google Scholar
• Ribas A, Dummer R, Puzanov I, VanderWalde A, Andtbacka RHI, Michielin O, Olszanski AJ, Malvehy J, Cebon J, Fernandez E, et al. Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy. Cell. 2017;170(6):1109–15. doi:https://doi.org/10.1016/j.cell.2017.08.027.
   PubMed Web of Science ®Google Scholar
• Bacac M, Klein C, Umana P. CEA TCB: A novel head-to-tail 2:1 T cell bispecific antibody for treatment of CEA-positive solid tumors. Oncoimmunology. 2016;5(8):e1203498. doi:https://doi.org/10.1080/2162402X.2016.1203498.
   PubMed Web of Science ®Google Scholar
• Marin-Acevedo JA, Soyano AE, Dholaria B, Knutson KL, Lou Y. Cancer immunotherapy beyond immune checkpoint inhibitors. J Hematol Oncol. 2018;11(1):8. doi:https://doi.org/10.1186/s13045-017-0552-6.
   PubMed Web of Science ®Google Scholar
• Cesson V, Stirnemann K, Robert B, Luescher I, Filleron T, Corradin G, Mach J-P, Donda A. Active antiviral T-lymphocyte response can be redirected against tumor cells by antitumor antibody x MHC/viral peptide conjugates. Clin Cancer Res. 2006;12(24):7422–30. doi:https://doi.org/10.1158/1078-0432.ccr-06-1862.
   PubMedGoogle Scholar
• Lev A, Noy R, Oved K, Novak H, Segal D, Walden P, Zehn D, Reiter Y. Tumor-specific Ab-mediated targeting of MHC-peptide complexes induces regression of human tumor xenografts in vivo. Proc Natl Acad Sci U S A. 2004;101(24):9051–56. doi:https://doi.org/10.1073/pnas.0403222101.
   PubMedGoogle Scholar
• Schmittnaegel M, Levitsky V, Hoffmann E, Georges G, Mundigl O, Klein C, Knoetgen H. Committing cytomegalovirus-specific CD8 T cells to eliminate tumor cells by bifunctional major histocompatibility class I antibody fusion molecules. Cancer Immunol Res. 2015;3(7):764–76. doi:https://doi.org/10.1158/2326-6066.CIR-15-0037.
   PubMedGoogle Scholar
• Khan N, Shariff N, Cobbold M, Bruton R, Ainsworth JA, Sinclair AJ, Nayak L, Moss PAH. Cytomegalovirus seropositivity drives the CD8 T cell repertoire toward greater clonality in healthy elderly individuals. J Immunol. 2002;169(4):1984–92. doi:https://doi.org/10.4049/jimmunol.169.4.1984.
   PubMed Web of Science ®Google Scholar
• Solberg OD, Mack SJ, Lancaster AK, Single RM, Tsai Y, Sanchez-Mazas A, Thomson G. Balancing selection and heterogeneity across the classical human leukocyte antigen loci: a meta-analytic review of 497 population studies. Hum Immunol. 2008;69(7):443–64. doi:https://doi.org/10.1016/j.humimm.2008.05.001.
   PubMed Web of Science ®Google Scholar
• Schmidt C. The struggle to do no harm in clinical trials. Nature. 2017;552(7685):S74–S5. doi:https://doi.org/10.1038/d41586-017-08705-4.
   Google Scholar
• De Vries J, Figdor C. Immunotherapy: cancer vaccine triggers antiviral-type defences. Nature. 2016;534(7607):329–31. doi:https://doi.org/10.1038/nature18443.
   PubMedGoogle Scholar
• Kranz LM, Diken M, Haas H, Kreiter S, Loquai C, Reuter KC, Meng M, Fritz D, Vascotto F, Hefesha H, et al. Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy. Nature. 2016;534(7607):396–401. doi:https://doi.org/10.1038/nature18300.
   PubMed Web of Science ®Google Scholar
• Simoni Y, Becht E, Fehlings M, Loh CY, Koo SL, Teng KWW, Yeong JPS, Nahar R, Zhang T, Kared H, et al. Bystander CD8(+) T cells are abundant and phenotypically distinct in human tumour infiltrates. Nature. 2018;557:575–79. doi:https://doi.org/10.1038/s41586-018-0130-2.
   PubMed Web of Science ®Google Scholar
• Schmittnaegel M, Hoffmann E, Imhof-Jung S, Fischer C, Drabner G, Georges G, Klein C, Knoetgen H. A new class of bifunctional major histocompatibility class I antibody fusion molecules to redirect CD8 T cells. Mol Cancer Ther. 2016;15(9):2130–42. doi:https://doi.org/10.1158/1535-7163.MCT-16-0207.
   PubMedGoogle Scholar
• Lev A, Novak H, Segal D, Reiter Y. Recruitment of CTL activity by tumor-specific antibody-mediated targeting of single-chain class I MHC-peptide complexes. J Immunol. 2002;169(6):2988–96. doi:https://doi.org/10.4049/jimmunol.169.6.2988.
   PubMedGoogle Scholar
• Novak H, Noy R, Oved K, Segal D, Wels WS, Reiter Y. Selective antibody-mediated targeting of class I MHC to EGFR-expressing tumor cells induces potent antitumor CTL activity in vitro and in vivo. Int J Cancer. 2007;120(2):329–36. doi:https://doi.org/10.1002/ijc.22168.
   PubMedGoogle Scholar
• King BC, Hamblin AD, Savage PM, Douglas LR, Hansen TH, French RR, Johnson PWM, Glennie MJ. Antibody-peptide-MHC fusion conjugates target non-cognate T cells to kill tumour cells. Cancer Immunol Immunother. 2013;62(6):1093–105. doi:https://doi.org/10.1007/s00262-013-1408-8.
   PubMedGoogle Scholar
• Wills MR, Carmichael AJ, Mynard K, Jin X, Weekes MP, Plachter B, Sissons JG. The human cytotoxic T-lymphocyte (CTL) response to cytomegalovirus is dominated by structural protein pp65: frequency, specificity, and T-cell receptor usage of pp65-specific CTL. J Virol. 1996;70(11):7569–79. doi:https://doi.org/10.1128/JVI.70.11.7569-7579.1996.
   PubMed Web of Science ®Google Scholar
• Gratama JW, Brooimans RA, van der Holt B, Sintnicolaas K, van Doornum G, Niesters HG, Löwenberg B, Cornelissen JJ. Monitoring cytomegalovirus IE-1 and pp65-specific CD4+ and CD8+ T-cell responses after allogeneic stem cell transplantation may identify patients at risk for recurrent CMV reactivations. Cytometry B Clin Cytom. 2008;74(4):211–20. doi:https://doi.org/10.1002/cyto.b.20420.
   PubMedGoogle Scholar
• Burnstein P, Brody NI. Suppression of the delayed type hypersensitivity response by tumor facilitating factor of B16 melanoma. A tumor factor suppresses immune responses. J Dermatol Surg Oncol. 1993;19(6):543–52. doi:https://doi.org/10.1111/j.1524-4725.1993.tb00388.x.
   PubMedGoogle Scholar
• Curran MA, Montalvo W, Yagita H, Allison JP. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci U S A. 2010;107(9):4275–80. doi:https://doi.org/10.1073/pnas.0915174107.
   PubMed Web of Science ®Google Scholar
• Laverman P, van der Geest T, Terry SY, Gerrits D, Walgreen B, Helsen MM, Nayak TK, Freimoser-Grundschober A, Waldhauer I, Hosse RJ, et al. Immuno-PET and immuno-SPECT of rheumatoid arthritis with radiolabeled anti-fibroblast activation protein antibody correlates with severity of arthritis. J Nucl Med. 2015;56(5):778–83. doi:https://doi.org/10.2967/jnumed.114.152959.
   PubMed Web of Science ®Google Scholar
• Brunker P, Wartha K, Friess T, Grau-Richards S, Waldhauer I, Koller CF, Weiser B, Majety M, Runza V, Niu H, et al. RG7386, a novel tetravalent FAP-DR5 antibody, effectively triggers FAP-dependent, avidity-driven DR5 hyperclustering and tumor cell apoptosis. Mol Cancer Ther. 2016;15(5):946–57. doi:https://doi.org/10.1158/1535-7163.MCT-15-0647.
   PubMed Web of Science ®Google Scholar
• Schaefer W, Regula JT, Bahner M, Schanzer J, Croasdale R, Durr H, Gassner C, Georges G, Kettenberger H, Imhof-Jung S, et al. Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies. Proc Natl Acad Sci U S A. 2011;108(27):11187–92. doi:https://doi.org/10.1073/pnas.1019002108.
   PubMed Web of Science ®Google Scholar
• Arduin E, Arora S, Bamert PR, Kuiper T, Popp S, Geisse S, Grau R, Calzascia T, Zenke G, Kovarik J, et al. Highly reduced binding to high and low affinity mouse Fc gamma receptors by L234A/L235A and N297A Fc mutations engineered into mouse IgG2a. Mol Immunol. 2015;63(2):456–63. doi:https://doi.org/10.1016/j.molimm.2014.09.017.
   PubMed Web of Science ®Google Scholar
• Baehner MJS, Kubbies M, Moessner E, Schlothauer T Genentech, assignee. ANTIBODY Fc VARIANTS 2012.
   Google Scholar
• Ridgway JB, Presta LG, Carter P. ‘Knobs-into-holes’ engineering of antibody CH3 domains for heavy chain heterodimerization. Protein Eng. 1996;9(7):617–21. doi:https://doi.org/10.1093/protein/9.7.617.
   PubMedGoogle Scholar
• Leo O, Foo M, Sachs DH, Samelson LE, Bluestone JA. Identification of a monoclonal antibody specific for a murine T3 polypeptide. Proc Natl Acad Sci U S A. 1987;84(5):1374–78. doi:https://doi.org/10.1073/pnas.84.5.1374.
   PubMed Web of Science ®Google Scholar
• Alegre ML, Vandenabeele P, Depierreux M, Florquin S, Deschodt-Lanckman M, Flamand V, Moser M, Leo O, Urbain J, Fiers W. Cytokine release syndrome induced by the 145-2C11 anti-CD3 monoclonal antibody in mice: prevention by high doses of methylprednisolone. J Immunol. 1991;146(4):1184–91.
   PubMed Web of Science ®Google Scholar
• Gunasekaran K, Pentony M, Shen M, Garrett L, Forte C, Woodward A, Ng SB, Born T, Retter M, Manchulenko K, et al. Enhancing antibody Fc heterodimer formation through electrostatic steering effects: applications to bispecific molecules and monovalent IgG. J Biol Chem. 2010;285(25):19637–46. doi:https://doi.org/10.1074/jbc.M110.117382.
   PubMed Web of Science ®Google Scholar
• Fidler IJ, Nicolson GL. Organ selectivity for implantation survival and growth of B16 melanoma variant tumor lines. J Natl Cancer Inst. 1976;57(5):1199–202. doi:https://doi.org/10.1093/jnci/57.5.1199.
   PubMedGoogle Scholar
• Dobosz M, Ntziachristos V, Scheuer W, Strobel S. Multispectral fluorescence ultramicroscopy: three-dimensional visualization and automatic quantification of tumor morphology, drug penetration, and antiangiogenic treatment response. Neoplasia. 2014;16(1):1–13. doi:https://doi.org/10.1593/neo.131848.
   PubMedGoogle Scholar
• Sorensen MR, Pedersen SR, Lindkvist A, Christensen JP, Thomsen AR. Quantification of B16 melanoma cells in lungs using triplex Q-PCR–a new approach to evaluate melanoma cell metastasis and tumor control. PLoS One. 2014;9(1):e87831. doi:https://doi.org/10.1371/journal.pone.0087831.
   PubMedGoogle Scholar